DNA-directed RNA polymerase
Complex in Clostridium difficile that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
- Genes: 4
Who is on it, and how far along
Every drug ChEMBL records acting on RPOA, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Fidaxomicin | Approved | Merck & Co. (MSD) | Small molecule | InhibitorDNA-directed RNA polymerase inhibitor | 5 |
| Vancomycin Taper to Prevent Recurrent Clostridioides Difficile | Fidaxomicin | Phase 3 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | Jan 9, 2026 |
| STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection | Fidaxomicin | Not applicable | Not yet recruiting | Medical University of Warsaw | Aug 13, 2025 |
| Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy | Fidaxomicin | Early phase 1 | Recruiting | Medical College of Wisconsin | Mar 19, 2025 |
| Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease | Fidaxomicin | Phase 4 | Not yet recruiting | Brigham and Women's Hospital | Jan 27, 2025 |
| Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence | Fidaxomicin | Phase 3 | Recruiting | Benoit Guery | Mar 4, 2022 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363852, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets